Theranexus SA (FR:ALTHX) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Theranexus reports a slight increase in cash reserves to €1.9 million as of September 30, 2024, aided by a significant research tax credit. The company remains focused on advancing its treatments for rare neurological diseases, aiming to register its liquid miglustat formulation in Europe and initiate a phase 3 trial for Batten disease.
For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.